We can readily understand why investors are attracted to unprofitable companies. For example, although...
By John Vandermosten, CFA NASDAQ:TENX Tenax Therapeutics (NASDAQ:TENX) announced on October 31st that it had enrolled 15 of 36 patients in its Hemodynamic Evaluation of Levosimendan in Patients with PH-HFpEF (HELP) trial. The company also announced the average reduction in average pulmonary capillary wedge pressure (PCWP) for the successfully screened patients of 8 mmHg. As a reminder, the
By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT Tenax Therapeutics (NASDAQ:TENX) updated investors on its Hemodynamic Evaluation of Levosimendan in Patients with PH-HFpEF (HELP) trial status last week in a January 13, 2020 release. Twenty-four patients have been randomized and an 86% initial response rate has been observed in screened patients. The average reduction in
Tenax Therapeutics, Inc. (NASDAQ: TENX) announces last visit completed in Phase 2 levosimendan trial in PH-HFpEF. Top-line data readout in Q2.
Tenax Therapeutics, Inc. (NASDAQ: TENX) Enters Agreement For $2.75 Million in Registered Direct Offering
By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT Tenax Therapeutics, Inc. (NASDAQ:TENX) completed enrollment of its Hemodynamic Evaluation of Levosimendan in Patients with PH-HFpEF (HELP) and announced that the last patient has completed their final visit as of April 9. This 37 patient open-label trial achieved an 84% initial response rate for screened patients, and is
By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT First Quarter 2019 Financial and Operational Review Following the December 2018 activation of trial sites, Tenax Therapeutics, Inc. ...
By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT Second Quarter 2019 Financial and Operational Review Tenax Therapeutics, Inc. (NASDAQ:TENX) began activating sites for its H emodynamic E valuation of L evosimendan in P atients with PH-HFpEF (HELP) trial in late 2018. After a thorough screening process, the first patient was
Tenax Therapeutics, Inc. (NASDAQ: TENX) announces enrollment completed in Phase 2 levosimendan HELP study
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
The big shareholder groups in Tenax Therapeutics, Inc. (NASDAQ:TENX) have power over the company. Institutions will...
If you own shares in Tenax Therapeutics, Inc. (NASDAQ:TENX) then it's worth thinking about how it contributes to the...